This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cushion, M. T.
Right arrow Articles by Kloepfer, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cushion, M. T.
Right arrow Articles by Kloepfer, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 02 1997, 379-384, Vol 41, No. 2
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents

MT Cushion, F Chen and N Kloepfer
Department of Internal Medicine, University of Cincinnati College of Medicine, Ohio 45267-0560, USA. cushiomt@ucbeh.san.uc.edu

A series of over 60 agents representing several different classes of compounds were evaluated for their effects on the ATP pools of Pneumocystis carinii populations derived from immunosuppressed rats. A cytotoxicity assay based on an ATP-driven bioluminescent reaction was used to determine the concentration of agent which decreased the P. carinii ATP pools by 50% versus untreated controls (IC50). A ranking system based on the IC50 value was devised for comparison of relative responses among the compounds evaluated in the cytotoxic assay and for comparison to in vivo efficacy. With few exceptions, there was a strong correlation between results from the ATP assay and the performance of the compound in vivo. Antibiotics, with the exception of trimethoprim- sulfamethoxazole (TMP-SMX), were ineffective at reducing the ATP pools and were not active clinically or in the rat model of P. carinii pneumonia. Likewise, other agents not expected to be effective, e.g., antiviral compounds, did not show activity. Standard anti-P. carinii compounds, e.g., TMP-SMX, pentamidine, and dapsone, dramatically reduced ATP levels. Analogs of the quinone and topoisomerase inhibitor groups were shown to reduce ATP concentrations and hold promise for further in vivo investigation. The cytotoxicity assay provides a rapid assessment of response, does not rely on replicating organisms, and should be useful for assessment of structure-function relationships.


This article has been cited by other articles:

  • Cushion, M. T., Collins, M. S., Linke, M. J. (2009). Biofilm Formation by Pneumocystis spp.. Eukaryot Cell 8: 197-206 [Abstract] [Full Text]  
  • Cushion, M. T., Walzer, P. D., Ashbaugh, A., Rebholz, S., Brubaker, R., Vanden Eynde, J. J., Mayence, A., Huang, T. L. (2006). In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice.. Antimicrob. Agents Chemother. 50: 2337-2343 [Abstract] [Full Text]  
  • Cushion, M. T., Walzer, P. D., Collins, M. S., Rebholz, S., Vanden Eynde, J. J., Mayence, A., Huang, T. L. (2004). Highly Active Anti-Pneumocystis carinii Compounds in a Library of Novel Piperazine-Linked Bisbenzamidines and Related Compounds. Antimicrob. Agents Chemother. 48: 4209-4216 [Abstract] [Full Text]  
  • Zhang, J., Zhu, J., Imrich, A., Cushion, M., Kinane, T. B., Koziel, H. (2004). Pneumocystis Activates Human Alveolar Macrophage NF-{kappa}B Signaling through Mannose Receptors. Infect. Immun. 72: 3147-3160 [Abstract] [Full Text]  
  • Van Dross, R. T., Sanders, M. M. (2002). Molecular Characterization of Recombinant Pneumocystis carinii Topoisomerase I: Differential Interactions with Human Topoisomerase I Poisons and Pentamidine. Antimicrob. Agents Chemother. 46: 2145-2154 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A. (2002). Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia. Antimicrob. Agents Chemother. 46: 514-516 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A., Collins, M., Cushion, M. T. (2001). In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 3234-3237 [Abstract] [Full Text]  
  • Cushion, M. T., Orr, S., Keely, S. P., Stringer, J. R. (2001). Time between Inoculations and Karyotype Forms of Pneumocystis carinii f. sp. carinii Influence Outcome of Experimental Coinfections in Rats. Infect. Immun. 69: 97-107 [Abstract] [Full Text]  
  • Cirioni, O., Giacometti, A., Barchiesi, F., Scalise, G. (2000). Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46: 577-582 [Abstract] [Full Text]  
  • Kaneshiro, E. S., Collins, M. S., Cushion, M. T. (2000). Inhibitors of Sterol Biosynthesis and Amphotericin B Reduce the Viability of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother. 44: 1630-1638 [Abstract] [Full Text]  
  • Cushion, M. T., Collins, M., Hazra, B., Kaneshiro, E. S. (2000). Effects of Atovaquone and Diospyrin-Based Drugs on the Cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother. 44: 713-719 [Abstract] [Full Text]  
  • Cirioni, O., Giacometti, A., Barchiesi, F., Fortuna, M., Scalise, G. (1999). In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. J Antimicrob Chemother 44: 653-659 [Abstract] [Full Text]  
  • Merali, S., Frevert, U., Williams, J. H., Chin, K., Bryan, R., Clarkson, A. B. Jr. (1999). Continuous axenic cultivation of Pneumocystis carinii. Proc. Natl. Acad. Sci. USA 96: 2402-2407 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»